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Abstract
Introduction: Despite recent advances in the management of septic shock, mortality rates are still unacceptably
high. Early identification of the high-mortality risk group for early intervention remains an issue under exploration.
Vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR1) and
urokinase plasminogen activator (uPA) have diverse effects in the pathogenesis of sepsis, which involve pro-
inflammation, anti-inflammation, endothelial cell repair, and vascular permeability change. Their roles in predicting
mortality and organ dysfunction remain to be clarified.
Methods: Pneumonia-related septic shock patients from medical intensive care units were enrolled for this
prospective observational study. We also included 20 patients with pneumonia without organ dysfunction for
comparison. Plasma levels of VEGF and sVEGFR1 and uPA activity within 24 hours of shock onset were measured.
We compared plasma levels of these biomarkers with APACHE II scores between subgroups of patients, and
evaluated their predictive value for 28-day mortality and organ dysfunction.
Results: A total of 101 patients, including 81 with pneumonia-related septic shock and 20 with pneumonia
without organ dysfunction, were enrolled. Non-survivors of septic shock had significantly higher plasma sVEGFR1
levels (659.3 ± 1022.8 vs. 221.1 ± 268.9 pg/mL, respectively, P < 0.001) and uPA activity (47.2 ± 40.6 vs.
27.6 ± 17.2 units, respectively, P = 0.001) when compared with those of the survivors. Kaplan-Meier survival analysis
demonstrated significantly higher mortality in patients with higher levels of sVEGFR1 (P < 0.001) and uPA activity
(P = 0.031). In Cox regression analysis, plasma sVEGFR1 level was independently associated with, and best
predicted, the 28-day mortality of septic shock (HR: 1.55, 95% CI: 1.05-2.30). Plasma sVEGFR1 level and uPA activity
had good correlation with renal dysfunction, metabolic acidosis, and hematologic dysfunction; their levels
significantly increased when the number of organ dysfunctions increased. In multivariate analysis, plasma sVEGFR1
level (HR: 2.82, 95% CI: 1.17-6.81) and uPA activity (HR: 2.75, 95% CI: 1.06-7.13) were independent predictors of the
presence of concomitant multi-organ dysfunction. The predictive value of VEGF for mortality and organ
dysfunction was limited in pneumonia-related septic shock patients.
Conclusions: High plasma sVEGFR1 level in the early stage of pneumonia-related septic shock independently
predicted 28-day mortality and multi-organ dysfunction.
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Sepsis occurs as a result of a complex interaction
between the microorganism and the host immune
response, and systemic inflammatory response syndrome
is an important feature of sepsis [1,2]. Septic shock,
defined as sepsis combined with hypotension that is
refractory to fluid resuscitation, is the main cause of
death in patients with sepsis [3]. Even with advances in
current management, the mortality rate of septic shock
has remained around 40% to 70% [4,5]. Determination
of novel markers that are present in the early phase of
septic shock and that have good correlations with out-
come is essential for the management of septic shock.
These markers would not only help identify patients
with an extraordinarily high mortality risk (and who
thus deserve aggressive management) but also provide
potential therapeutic targets.
Endothelial cell dysfunction and disturbance of the
coagulation system have been proposed to be pivotal
factors in the pathophysiology of sepsis [2,6]. Vascular
endothelial growth factor (VEGF) is a glycoprotein that
is synthesized and released by vascular endothelial cells,
lung epithelium, platelets, and leukocytes [7]. Through
binding with the VEGF recep t o r ,V E G Fc a ne n h a n c e
angiogenesis and increase microvascular permeability,
which may lead to edema and hypotension [8,9]. VEGF
also has been found to promote the proliferation, migra-
tion, and survival of endothelial cells [10]. Three types
of VEGF receptors - fms-like tyrosine kinase (FLT-1,
VEGFR1), kinase-insert-domain-containing receptor
(KDR, VEGFR2), and fms-like tyrosine kinase-4 (Flt-4,
VEGFR3) - have been reported and are expressed mostly
on endothelial cells [11,12]. Soluble VEGFR1 (sVEGFR1)
is generated by alternative splicing of VEGFR1 mRNA
and functions as an intrinsic negative counterpart of
VEGF signaling [13]. Recently, animal and human stu-
dies have reported controversial results regarding the
association between VEGF, sVEGFR1 concentration, and
disease severity in sepsis and septic shock [14-17].
Urokinase plasminogen activator (uPA) is a serine
protease that catalyzes the conversion of plasminogen to
plasmin. In addition to having a role in fibrinolysis, uPA
has been described as being involved in the inflamma-
tory process and endothelial cell migration [18-20].
Furthermore, recent studies have indicated that uPA
plays a vital role in the process of VEGF-induced vascu-
lar permeability change [21], which may involve the
mechanism of septic shock. Despite the complex role of
uPA in sepsis, the impact of uPA on the outcome of
septic shock remains to be identified.
The purpose of this study was to evaluate the role of
endothelial cell-related biomarkers, including VEGF,
sVEGFR1, and uPA, with respect to the mortality of
patients with pneumonia-related septic shock. The
predictive values of these markers for disease severity
and organ dysfunction were also investigated.
Materials and methods
Patients
This prospective, observational study was conducted at
Taipei Veterans General Hospital, a tertiary medical
center in Taiwan. From January 2006 to February 2008,
all patients who were at least 18 years of age and who
were admitted to the medical intensive care unit (ICU)
and respiratory ICU were screened. Patients who had a
diagnosis of pneumonia and who fulfilled the American
College of Chest Physicians/Society of Critical Care
Medicine criteria for septic shock [1], which is defined
as refractory hypotension despite adequate fluid supple-
ment and the requirement of vasopressors to maintain
the mean arterial blood pressure of at least 65 mm Hg,
were eligible for enrollment. The diagnosis of pneumo-
nia was confirmed on the basis of typical clinical presen-
tations, fever, leukocytosis, and new infiltrates on chest
radiographs [22,23]. Patients with underlying malignan-
cies, autoimmune disorders, active thromboembolic dis-
e a s ea n dt h o s ew h of a i l e dt og i v ei n f o r m e dc o n s e n t
were excluded. During the same period, we also enrolled
20 patients who were from the general medical ward
and who had a diagnosis of pneumonia without sepsis
or organ dysfunction as a control group. All patients
were treated in accordance with the current treatment
guidelines, and broad-spectrum antibiotics were admi-
nistered within 1 hour of the onset of septic shock, as is
routine in our ICUs. The antibiotics were also adjusted
on the basis of the clinical response and the susceptibil-
ity profile of bacterial cultures. All patients with septic
shock received a physiological dose of corticosteroids
(hydrocortisone, 200 mg/day, divided in four doses).
The study protocol was approved by the Taipei Veterans
General Hospital Institutional Review Board, and the
study was conducted in accordance with the Declaration
of Helsinki. Written informed consent was obtained
from all participants or their authorized representatives
before enrollment.
Clinical evaluation
Demographic characteristics, underlying comorbidities,
disease severity, and organ dysfunction were determined
on the day of enrollment. Organ dysfunction was
defined as in a previous study [24]; the details of the
definition are provided as supplemental material (Addi-
tional file 1). Disease severity was evaluated by the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score on the day of enrollment. Multi-
organ dysfunction was defined as septic shock plus one
or more organ dysfunctions, and the severity of multi-
organ dysfunction was evaluated by the Sequential
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at 28 days and beyond was determined.
Blood sampling and biomarker measurement
Blood samples were collected from peripheral vessels
within 24 hours of shock onset and study entry. Plasma
was separated from whole blood and stored at -70°C
until analysis. Total forms of plasma VEGF and
sVEGFR1 concentrations were measured in duplicate
with commercial enzyme-linked immunosorbent assay
kits (Quantikine; R&D Systems, Inc., Minneapolis, MN,
USA). Plasma uPA activity was evaluated with a uPA
Activity Assay kit (Chemicon International, Temecula,
CA, USA).
Statistical analysis
Statistical analysis was performed with SPSS 14.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). Continuous vari-
ables between subgroups were compared with the
Mann-Whitney U test or independent t test, and catego-
rical variables were compared using Pearson’s chi-square
test. Binary logistic regression analysis was performed to
determine the independent variables for multi-organ
dysfunction. To determine the predictive accuracy of
biomarker levels for survival and organ dysfunction,
receiver operating characteristic (ROC) curves were con-
structed, and the areas under the curves (AUCs) were
calculated.
For survival analysis, patients were stratified into sub-
groups according to plasma biomarker levels. Survival
time was estimated by the Kaplan-Meier method, and
the log-rank test was used to compare mortality
between patients with quartile biomarker levels. Cen-
sored analysis was used since observation time was lim-
ited by discharge from the hospital. A multivariate Cox
proportional hazards regression model with forward
stepwise selection procedures was used to identify the
risk factors for 28-day mortality. A P value of less than
0.1 in the univariate analysis was required for a variable
to enter the multivariate model. A P value of less than
0.05 was considered statistically significant for all tests.
Results
Patient characteristics
The study profile showing the number of cases and rea-
sons for exclusion is shown in Figure 1. Ultimately, 81
patients with pneumonia complicated with septic shock
were enrolled in the study. We also enrolled 20 patients
with pneumonia without organ failure for comparison;
all of these patients survived and were successfully dis-
charged from the hospital. Among the 81 pneumonia
patients with septic shock, 43 died within 28 days
(28-day mortality of 53.1%), 11 died during their hospi-
tal stay after day 28 (hospital mortality of 66.7%), and
27 (33.3%) survived and were discharged from the hos-
pital. The demographic characteristics of all pneumonia
patients are shown in Table 1. The mean age of these
patients was 79.3 ± 10.9 years, and the majority were
male (87/101, 86.1%). There were no differences in age,
gender, and underlying comorbidities between the
patients with pneumonia without organ dysfunction, the
septic shock survivors, and the non-survivors at day 28.
The non-survivors of pneumonia-related septic shock
had a significantly higher APACHE II score (P <0 . 0 0 1 ) ,
lower PaO2/FiO2 (arterial partial pressure of oxygen/
fraction of inspired oxygen) ratio (P < 0.001), higher
SOFA score (P < 0.001), and more organ dysfunctions
as compared with the survivors. Pathogens were identi-
fied more frequently in patients with pneumonia-related
septic shock as compared with those without organ dys-
function (P < 0.001).
Plasma biomarker levels in patients with pneumonia and
septic shock
The mean VEGF level of the septic shock non-survivors
was 386.5 ± 524.1 pg/mL, which was significantly lower
than that of the patients with pneumonia without organ
dysfunction (688.9 ± 616.9 pg/mL, P =0 . 0 0 5 )b u tc o m -
parable to that of the septic shock survivors (219.9 ±
232.1 pg/mL, P = 0.455) (Figure 2). The mean sVEGFR1
level of the septic shock non-survivors was 659.3 ±
1,022.8 pg/mL, which was significantly higher than that
of the septic shock survivors (221.1 ± 268.9 pg/mL, P <
0.001) and those with pneumonia without organ dys-
function (199.3 ± 81.6 pg/mL, P=0.006). The mean
plasma uPA activity of the septic shock non-survivors
was 47.2 ± 40.6 units, which was significantly higher
than that of the septic shock survivors (27.6 ±
17.2 units, P = 0.001) but comparable to that of the
patients with pneumonia without organ dysfunction
(44.3 ± 17.9 units, P = 0.243).
Predictive value of plasma biomarkers for 28-day
mortality
The ROC curves of day-1 plasma levels of VEGF and
sVEGFR1, uPA activities, and APACHE II scores in pre-
dicting 28-day mortality of septic shock patients are
shown in Figure 3. APACHE II score, sVEGFR1 level, and
uPA activity were good predictors of 28-day mortality, and
the AUCs were 0.861 (95% confidence interval [CI] 0.765
to 0.929, P < 0.001), 0.756 (95% CI 0.647 to 0.846, P <
0.001), and 0.716 (95% CI 0.646 to 0.812, P < 0.001),
respectively. The AUC of plasma VEGF level for 28-day
mortality was 0.55 (95% CI 0.434 to 0.662, P = 0.46).
The Kaplan-Meier analyses of survival according to
quartile biomarker levels in septic shock patients are
shown in Figure 4. Patients with higher plasma
sVEGFR1 levels and uPA activities had significantly
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as compared with those with lower levels. The absolute
difference in survival between the subgroups as repre-
sented by these biomarkers was evident from the early
stage of septic shock. The survival curves overlapped
between patients with different plasma VEGF levels (P =
0.58). Based on the optimal cutoff point of plasma
sVEGFR1 level determined from the ROC curve (Figure
2), the Kaplan-Meier analysis of survival of the sub-
groups of patients dividedb yA P A C H EI Is c o r e sa n d
Figure 1 Study profile demonstrating the number of cases and reasons for exclusion. ICU, intensive care unit.
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an APACHE II score of at least 25, those with higher
sVEGFR1 levels (>224 pg/mL) had a significantly higher
mortality rate as compared with those with lower
sVEGFR1 levels (P < 0.001). Similarly, in patients with
an APACHE II score of less than 25, a trend toward
higher mortality was found in those with higher
sVEGFR1 levels (>224 pg/mL), but statistical signifi-
cance was not achieved (P = 0.11).
Cox regression analysis models by quartile plasma bio-
marker levels, APACHE II scores, and comorbidities for
the hazard ratio of mortality in septic shock patients are
shown in Table 2. Both APACHE II score and increased
plasma sVEGFR1 level were significant risk factors of
28-day mortality. The hazard ratios were 1.55 (P =
0.029) for every escalation of the sVEGFR1 quartile and
2.30 (P < 0.001) for that of APACHE II scores.
sVEGFR1 and uPA levels predict multi-organ dysfunction
The occurrence of organ dysfunction, including acute
respiratory distress syndrome, renal dysfunction, meta-
bolic acidosis, and hematologic dysfunction, based on
Table 1 Demographic characteristics of patients with pneumonia without organ dysfunction and those with
pneumonia-related septic shock
Pneumonia with septic shock
a
Pneumonia without organ dysfunction Survivors Non-survivors P value
b
Number of patients 20 38 43
Age, years 77.2 (14.1) 79.9 (7.9) 79.7 (11.7) 0.93
Male gender 18 (90%) 32 (84.2%) 37 (86%) 0.81
Comorbidity
Obstructive airway disease 3 (15%) 10 (26.3%) 9 (20.9%) 0.57
Interstitial lung disease 1 (5%) 6 (15.8%) 5 (11.6%) 0.59
Congestive heart failure 1 (5%) 5 (13.2%) 4 (9.3%) 0.58
Diabetes mellitus 6 (30%) 10 (26.3%) 14 (32.6%) 0.54
Chronic renal insufficiency 1 (5%) 5 (13.2%) 9 (20.9%) 0.36
Pathogens in sputum culture
Gram-positive bacteria 3 (15%) 10 (26.3%) 8 (18.6%) 0.41
Gram-negative bacteria 3 (15%) 32 (84.2%) 30 (69.8%) 0.12
Pathogens in blood culture
Gram-positive bacteria 0 4 (10.5%) 1 (2.3%) 0.18
Gram-negative bacteria 0 4 (10.5%) 11 (25.6%) 0.08
Source of pneumonia 0.38
Community-acquired pneumonia 20 (100%) 24 (63.2%) 21 (48.8%)
Hospital-acquired pneumonia 0 7 (18.4%) 9 (20.9%)
Ventilator-acquired pneumonia 0 7 (18.4%) 13 (30.2%)
Disease severity
APACHE II score - 24.1 (5.1) 33.4 (7.1) <0.001
PaO2/FiO2 ratio - 214.2 (87.6) 156.8 (100.3) <0.001
Organ dysfunction
c
Renal dysfunction - 10 (26.3%) 28 (65.1%) <0.001
Hematologic dysfunction - 7 (18.4%) 20 (46.5%) 0.007
Metabolic acidosis - 3 (7.9%) 20 (46.5%) <0.001
Adult respiratory distress syndrome - 18 (47.4%) 32 (74.4%) 0.012
Number of organ dysfunctions
≥2 organ failures (including shock) - 23 (60.5%) 39 (90.7%) 0.001
≥3 organ failures (including shock) - 5 (13.2%) 29 (67.4%) <0.001
≥4 organ failures (including shock) - 2 (5.3%) 19 (44.2%) <0.001
SOFA score - 10.6 (2.5) 12.5 (2.6) <0.001
Hospital length of stay, days 8.4 (3.6) 64.7 (40.5) 22.4 (15.4) <0.001
Intensive care unit length of stay, days - 40.6 (25.1) 18.3 (12.0) <0.001
Combined with other infection sources - 8 (21.1%) 6 (14%) 0.40
Data are presented as number (percentage), except for age, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, arterial partial pressure of
oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio, Sequential Organ Failure Assessment (SOFA) score, hospital length of stay, and intensive care unit length of
stay, which are presented as mean (standard deviation).
aPatients with pneumonia with septic shock were divided according to survival status at day 28;
bP value
represents differences between survivors and non-survivors of pneumonia-related septic shock;
corgan dysfunction was determined on the day of enrollment.
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plasma biomarker levels were stratified according to the
optimal cutoff point determined from the ROC curve
(Figure 3), patients with higher sVEGFR1 levels and
uPA activities had significantly higher incidences of
organ dysfunction. The mean plasma sVEGFR1 levels
and uPA activities of patients with various numbers of
organ dysfunctions are also shown in Figure 6. Patients
with more organ dysfunctions had significantly higher
plasma sVEGFR1 levels and uPA activities compared
with those with only one organ dysfunction.
Multivariate analysis by quartile plasma biomarker
levels, APACHE II scores, and comorbidities for the
hazard ratio of multi-organ dysfunction are shown in
Table 3. Increased plasma sVEGFR1 levels and uPA
activities were independent risk factors for multi-organ
dysfunction. The hazard ratios were 2.82 (P = 0.021) for
every escalation of the sVEGFR1 quartile and 2.75 (P =
0.037) for that of the uPA quartile.
Discussion
This study demonstrated that plasma sVEGFR1 level and
uPA activity are valuable predictors of 28-day mortality
in patients with pneumonia-related septic shock. The
role of the initial plasma VEGF level in predicting 28-day
mortality and organ dysfunction was insignificant. In
multivariate Cox regression analysis, the plasma
sVEGFR1 level was the most significant plasma biomar-
ker for 28-day mortality. We also found sVEGFR1 level
and uPA activity to be the independent predictors of
multi-organ dysfunction. The role of these biomarkers in
the pathogenesis of sepsis deserves further exploration.
VEGF has been reported to be an important mediator
in increasing vascular permeability and exacerbating
hemodynamic instability [9]. Signaling of the VEGF
pathway also contributes to the proliferation and survi-
val of endothelial cells [10]. Previous studies have con-
cluded that plasma VEGF levels are elevated in patients
with sepsis (as compared with healthy controls) and
have good correlation with organ dysfunction and dis-
ease severity [14-16,25]. However, studies evaluating the
predictive value of plasma VEGF levels with respect to
mortality have yielded controversial results [15,25]. In
our study, there was no statistical difference in plasma
VEGF levels between the survivors and non-survivors of
pneumonia-related septic shock. The results of our
study, and those of previous reports, indicate that the
complex effect of VEGF in sepsis remains to be clarified.
Our study showed that the plasma sVEGFR1 level,
unlike VEGR level, was an independent predictive factor
for mortality and the presence of concomitant multi-
Figure 2 Mean plasma biomarker levels in patient subgroups.
(a) Vascular endothelial growth factor (VEGF) and (b) soluble
vascular endothelial growth factor receptor 1 (sVEGFR1) levels and
(c) urokinase plasminogen activator (uPA) activity in patients with
pneumonia without organ dysfunction (open bar), pneumonia-
related septic shock survivors at day 28 (shaded bar), and non-
survivors at day 28 (solid bar). Means and standard errors of the
mean of plasma biomarker levels are shown. Significance was tested
with the two-sided Mann-Whitney U test.
Yang et al. Critical Care 2011, 15:R11
http://ccforum.com/content/15/1/R11
Page 6 of 11Figure 3 Receiver operator characteristic (ROC) curves of plasma biomarker levels and Acute Physiology and Chronic Health
Evaluation II (APACHE II) scores for predicting 28-day mortality. ROC curves plotted for studying the utility of plasma biomarker levels and
APACHE II scores in predicting 28-day mortality of pneumonia-related septic shock patients are shown. The areas under the ROC curves (AUCs)
for soluble vascular endothelial growth factor receptor 1 (sVEGFR1), urokinase plasminogen activator (uPA), and APACHE II scores were
significantly greater than 0.5. The optimal cutoff points for each biomarker and APACHE II score, along with their predictive values for the 28-day
mortality of patients with pneumonia-related septic shock, are listed in the attached table. CI, confidence interval; VEGF, vascular endothelial
growth factor.
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that, as compared with patients with high APACHE II
scores (≥25) and lower sVEGFR1 levels (≤224 pg/mL),
t h o s ew i t hh i g hA P A C H EI Is c o r e s( ≥25) and higher
sVEGFR1 levels (>224 pg/mL) had significantly higher
mortality. Probably owing to relatively small sample size,
there was no statistical difference in mortality rate
between patients with higher or lower sVEGFR1 levels
in the subgroup of patients with lower APACHE II
scores (<25); nevertheless, a trend toward higher mortal-
ity in those with higher sVEGFR1 levels existed. Our
findings indicated that combining the APACHE II score
and sVEGFR1 level yield better discriminative power in
mortality prediction. This further clarifies the clinical
application of plasma sVEGFR1 level in patients with
septic shock.
The soluble form of VEGFR1 is a splicing variant of
VEGFR1 and exerts a negative influence on VEGF signal-
ing. The role of sVEGFR1 in sepsis is probably dual,
involving endothelial cell damage and an anti-inflamma-
tory effect. The upregulation of VEGF and VEGFR1 on
the cell surface is widely reported after endothelial injury
and functions as a protective mechanism that enhances
Table 2 Cox proportional hazards models for mortality
prediction by comorbidities, biomarkers, and APACHE II
score in patients with pneumonia-related septic shock
Univariate Cox
model
Multivariate Cox
model
Variables HR (95%
CI)
P
value
HR (95%
CI)
P
value
Age 1.00 (0.97-
1.03)
0.92
Comorbidity
Diabetes mellitus 1.15 (0.61-
2.18)
0.66
Obstructive airway
disease
0.79 (0.38-
1.63)
0.52
Interstitial lung
disease
0.72 (0.29-
1.83)
0.50
Chronic renal
insufficiency
1.24 (0.60-
2.58)
0.56
Congestive heart
failure
0.74 (0.26-
2.05)
0.56
sVEGFR1, quartile 1.97 (1.46-
2.65)
<0.001 1.55 (1.05-
2.30)
0.029
uPA, quartile 1.58 (1.19-
2.10)
0.002 1.18 (0.77-
1.79)
0.45
VEGF, quartile 1.09 (0.83-
1.44)
0.52
APACHE II, quartile 2.44 (1.78-
3.35)
<0.001 2.30 (1.53-
3.49)
<0.001
Relative risk and 95% confidence interval (CI) were derived from the Cox
proportional hazards regression model. APACHE II, Acute Physiology and
Chronic Health Evaluation II; HR, hazard ratio; sVEGFR1, soluble vascular
endothelial growth factor receptor 1; uPA, urokinase plasminogen activator;
VEGF, vascular endothelial growth factor.
Figure 4 Kaplan-Meier survival curves of patients with
pneumonia-related septic shock, stratified by day-1 plasma
biomarker levels. Patients were categorized into three groups based
on quartile levels of (a) vascular endothelial growth factor (VEGF), (b)
soluble vascular endothelial growth factor receptor 1 (sVEGFR1), and
(c) urokinase plasminogen activator (uPA), (d) combining sVEGFR1
levels and Acute Physiology and Chronic Health Evaluation II
(APACHE II) scores. Significances were tested with the log-rank test.
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[26,27]. The inhibitory effect of sVEGFR1 in VEGF sig-
naling may hamper the process of endothelial repair.
Therefore, the elevation of plasma sVEGFR1 level in
sepsis may lead to disease progression and organ dys-
function. Meanwhile, VEGF has been reported to have
pro-inflammatory properties; an in vitro study showed
VEGFR1 to be involved in the migration of monocytes/
macrophages [28]. As a negative counterpart in VEGF
signaling, elevation of sVEGFR1 will lead to an anti-
inflammatory state; however, uncontrolled elevation of
sVEGFR1 may also cause profound immune depression
and lead to a worse outcome in patients with septic
shock. Therefore, the opposing actions of sVEGFR1 on
VEGF may have contributed to the inconsistent results
regarding the role of VEGF in sepsis in the present and
previous studies.
The role of uPA in the pathogenesis of sepsis is prob-
ably complex. Through the conversion of plasminogen
to plasmin, uPA may play an antithrombotic role in sep-
sis. uPA also has pro-inflammatory effects, including
cytokine induction, neutrophil activation, and enhance-
ment of lipopolysaccharide-related inflammation [19,29].
The interaction between uPA and VEGF has been
described; pro-uPA can be activated by VEGF on
endothelial cells and is involved in the VEGF-related
angiogenic process [30]. Behzadian and colleagues [21]
f o u n dt h a tt h ed e l a y e dp h a s eo fV E G F - i n d u c e dp e r m e -
ability change could be blocked by anti-uPA antibodies
in vitro and concluded that uPA is an important media-
tor in the process of VEGF-mediated permeability
change. The role of uPA, despite its diverse effects, in
patients with septic shock remains to be determined.
A few previous studies have reported increased uPA
activity in patients with severe infection or sepsis
[31,32]. In this study, for the first time, we identified
uPA activity as an independent predictor of concomitant
multi-organ dysfunction in patients with septic shock. In
addition to antithrombotic effects, the elevation of uPA
in sepsis may involve the VEGF pathway, which includes
endothelial cell repair and migration, angiogenesis, and
vascular permeability change.
The major limitations of this study include the small
number of cases and low patient population diversity.
A relatively small number of cases may lead to a wide
Figure 5 Organ dysfunctions in patients with pneumonia-
related septic shock. The occurrence of organ dysfunction at the
onset of septic shock was compared based on plasma (a) soluble
vascular endothelial growth factor receptor 1 (sVEGFR1) levels and
(b) urokinase plasminogen activator (uPA) activities above the
optimal cutoff points (solid bars) and below the optimal cutoff
points (shaded bars). Significance was tested by Pearson’s chi-square
test. ARDS, acute respiratory distress syndrome.
Figure 6 Plasma soluble vascular endothelial growth factor
receptor 1 (sVEGFR1) levels and urokinase plasminogen
activator (uPA) activities in pneumonia-related septic shock
patients with various numbers of organ dysfunctions. Means
and standard errors of the mean of the sVEGFR1 levels (solid bars)
and uPA activities (shaded bars) are shown. Significance was tested
with the two-sided Mann-Whitney U test.
Yang et al. Critical Care 2011, 15:R11
http://ccforum.com/content/15/1/R11
Page 9 of 11range of standard deviations of biomarker levels. Only
patients with pneumonia-related septic shock were
enrolled, and most of them were older males with pro-
found disease severity. The homogeneity of the patients
reflects the characteristics of our hospital (that is, a
veterans hospital). Nevertheless, the low diversity mini-
mizes the confounding factors in the patient population
and also allows our findings to be reliably applied to
older pneumonia patients with critical illnesses. Another
limitation is that blood samples were collected only
from the first day of shock onset; therefore, the variation
trend of these biomarkers in the course of septic shock
could not be evaluated in the present study.
Conclusions
Our results suggest that sVEGFR1 level determined in
the early phase of pneumonia-related septic shock is a
promising predictor for multi-organ dysfunction and
28-day mortality. The immunosuppressive effect of
sVEGFR1 makes it a novel marker of immunoparalysis
in the pathogenesis of sepsis. However, the correlation
between sVEGFR1 and uPA and their roles in endothe-
lial dysfunction deserve more investigation. Further stu-
dies with a larger number of patients and diverse
infectious origins are warranted to identify the role of
these biomarkers in septic shock.
Key messages
￿ Plasma soluble vascular endothelial growth factor 1
(sVEGFR1) level in the early phase of pneumonia-related
septic shock is an independent predictor of 28-day mor-
t a l i t ya n dt h ep r e s e n c eo fc oncomitant multi-organ
dysfunction.
￿ Combining Acute Physiology and Chronic Health
Evaluation II (APACHE II) score and plasma sVEGFR1
level can help in identifying patients with an extremely
high risk of mortality.
￿ Plasma urokinase plasminogen activator activity in
the early phase of pneumonia-related septic shock is an
independent predictor of the presence of concomitant
multi-organ dysfunction.
￿ The predictive value of plasma vascular endothelial
growth factor level for 28-day mortality and concomitant
multi-organ dysfunction is limited in the present study.
Additional material
Additional file 1: Criteria for organ dysfunction. ARDS, acute
respiratory distress syndrome.
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